Hinova Pharmaceuticals Inc. (SHA:688302)

China · Delayed Price · Currency is CNY

33.15

+0.75 (2.31%)

At close: Aug 4, 2026

-45.65% (1Y)

Market Cap	3.28B -45.6%
Revenue (ttm)	46.50M +12,574.7%
Net Income	-135.03M
EPS	-1.37
Shares Out	99.02M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,404,089
Open	32.42
Previous Close	32.40
Day's Range	32.20 - 33.58
52-Week Range	31.90 - 71.98
Beta	-0.07
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Hinova Pharmaceuticals

Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, develops and produces therapeutics for cancers and metabolic syndromes. Its core product is Hainaan, a deuterium enzalutamide soft capsules for the treatment of prostate cancer; it also develops drugs based on proteolysis targeting chimera and deuteration technology. The company’s products pipeline includes HP518, a PROTAC molecule targeting advanced prostate cancer; HP537, a small-molecule anti-tumor drug; HP515, an orally administered which improves liver and blood biochemi... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2013

Employees 241

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688302

Full Company Profile

Financial Performance

In 2025, Hinova Pharmaceuticals's revenue was 20.47 million, an increase of 5480.12% compared to the previous year's 366,836. Losses were -137.25 million, -31.20% less than in 2024.

Financial Statements